(4-(Pyrrolidine-1-carbonyl)phenyl)boronic acid → 1-Methylethyl 4-({[4'-(1-pyrrolidinylcarbonyl)-4-biphenylyl]oxy}methyl)-1-piperidinecarboxylate
Reaction equation
[N:1]1([C:6]([C:8]2[CH:13]=[CH:12][C:11](B(O)O)=[CH:10][CH:9]=2)=[O:7])[CH2:5][CH2:4][CH2:3][CH2:2]1.Br[C:18]1[CH:23]=[CH:22][C:21]([O:24][CH2:25][CH:26]2[CH2:31][CH2:30][N:29]([C:32]([O:34][CH:35]([CH3:37])[CH3:36])=[O:33])[CH2:28][CH2:27]2)=[CH:20][CH:19]=1>>[N:1]1([C:6]([C:8]2[CH:13]=[CH:12][C:11]([C:18]3[CH:19]=[CH:20][C:21]([O:24][CH2:25][CH:26]4[CH2:27][CH2:28][N:29]([C:32]([O:34][CH:35]([CH3:37])[CH3:36])=[O:33])[CH2:30][CH2:31]4)=[CH:22][CH:23]=3)=[CH:10][CH:9]=2)=[O:7])[CH2:5][CH2:4][CH2:3][CH2:2]1Participants
3
Procedure
The title compound (8.6 mg, 19%) was prepared from [4-(1-pyrrolidinylcarbonyl)phenyl]boronic acid (21.9 mg, 0.1 mmol) and 1-methylethyl 4-{[(4-bromophenyl)oxy]methyl}-1-piperidinecarboxylate (Example 9, Step 2, 36 mg, 0.10 mmol) in a manner similar to Example 9, Step 3. LRMS (ESI), m/z 451 (M+H).